ACA

NEUTRALM&A

Arcosa, Inc.

2026-09-16

Price

$145.14

-0.01%

This is the 2026-09-16 snapshot — the signals and analysis for ACA as of this single trading day.

View full ACA research hub →

Score5.0Watchlist

Signals6/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume1.4xvs 20d avg

Analysis

Arcosa's price action is entirely dictated by its pending $150 per share all-cash acquisition by CRH, which was officially approved by stockholders on September 4. The exceptionally low realized volatility of 2.2% and technical signals like BOLLINGER_SQUEEZE and QUIET_STORM reflect classic merger arbitrage behavior as the stock pins near the deal price. The current RISK_ON macro regime, highlighted by ultra-low high-yield credit spreads (0.80%), provides high conviction that financing and systemic risks are negligible ahead of the expected Q1 2027 close.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSBOLLINGER SQUEEZEMARKET LEADERPERFECT STACKBARGAIN HUNTERDISTRIBUTION

Key Takeaways

Actionable Thesis: The stock is a pure merger arbitrage play anchored to CRH's $150/share all-cash buyout, which was overwhelmingly approved by stockholders.
Key Risk: The remaining spread to $150 hinges entirely on regulatory and antitrust approvals, making any delay or block the primary downside risk.
What to Watch: Monitor the $144.90 line-in-the-sand; a break below this level would indicate institutional fears regarding the deal's final closure.

← Back to 2026-09-16 View Full ACA History →Yahoo Finance &nearr;